http://www.fda.gov/cder/workshop.htm (choose Minimizing Medication Errors—Evaluating the Drug Naming Process; Public Meeting). Comments were to be received by July 15, 2003. However, in response to a request that the agency allow interested parties additional time to review and to submit comments on this issue, FDA is reopening the comment period on issues discussed at that meeting until September 5, 2003.

II. Comments

Interested persons may submit to the Division of Dockets Management (*see* **ADDRESSES**) written or electronic comments regarding this document. Submit a single copy of electronic comments or two paper copies of any mailed comments, except individuals may submit one paper copy. Comments are to be identified with the docket number found in brackets in the heading of this document. A copy of the document and received comments are available for public examination in the Division of Dockets Management between 9 a.m. and 4 p.m., Monday through Friday.

III. Electronic Access

Persons with access to the Internet may obtain the issues on which comments are requested at *http://www.fda.gov/cder/workshop.htm*. Paper copies of the questions may be obtained by contacting Mary Gross (*see* **FOR FURTHER INFORMATION CONTACT**).

Dated: July 31, 2003.

Jeffrey Shuren,

Assistant Commissioner for Policy.

[FR Doc. 03–20063 Filed 8–5–03; 8:45 am]

BILLING CODE 4160–01–S

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

Food and Drug Administration and National Institute of Allergy and Infectious Diseases; Public Workshop

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice of public workshop.

SUMMARY: The Food and Drug Administration (FDA) is announcing a public workshop, cosponsored with the National Institute of Allergy and Infectious Diseases (NIAID), regarding clinical trial design of febrile neutropenia and antifungal combination therapy. The public workshop is intended to provide information for and gain perspectives from advocacy groups, interested health care providers, academia, and industry organizations on various aspects of febrile neutropenic and antifungal drug development.

DATES: The public workshop will be held on Thursday, September 4, 2003, from 1 p.m. to 5 p.m.

ADDRESSES: The public meeting will be held at the Hyatt Regency Bethesda, One Bethesda Metro Center, Bethesda, MD 20814. Seating is limited and available on a first-come, first-served basis. *See* the **SUPPLEMENTARY INFORMATION** section for information on electronic registration.

FOR FURTHER INFORMATION CONTACT: John Powers or Leo Chan, Center for Drug Evaluation and Research (HFD–104), Food and Drug Administration, 9201 Corporate Blvd., Rockville, MD 20850, (301) 827–2530.

SUPPLEMENTARY INFORMATION: FDA is announcing a public workshop, cosponsored with NIAID, regarding two drug development scenarios: (1) Studies of empirical therapy in febrile neutropenic patients; and (2) clinical trial design considerations necessary to adequately determine safety and efficacy of antifungal combination therapies. Both agencies encourage individuals, patient advocates, industry, consumer groups, health care professionals, researchers, and other interested persons to attend this public workshop. The input from this public workshop will be used to develop topics for discussion at future meetings of the Antiviral Drugs Advisory Committee.

Because seating is limited, we are asking interested persons to register on a first-come, first-served basis. To register electronically, go to FDA's Web site at *http://www.fda.gov/cder/drug/antimicrobial/default.htm*. Those without access to the Internet can call (301) 827–2530 to register.

Dated: July 30, 2003.

Jeffrey Shuren,

Assistant Commissioner for Policy.

[FR Doc. 03–20064 Filed 8–5–03; 8:45 am]

BILLING CODE 4160–01–S

DEPARMENT OF HEALTH AND HUMAN SERVICES

Health Resources and Services Administration

[CFDA 93.145, HRSA 04–008]

AIDS Education and Training Centers, National Evaluation Center Cooperative Agreement (NECCA); Open Competition Announcement

AGENCY: Health Resources and Services Administration, HHS.

ACTION: Notice of Open Competition Cooperative Agreement.

SUMMARY: The Health Resources and Services Administration's (HRSA) HIV/AIDS Bureau (HAB) announces that applications will be accepted for fiscal year (FY) 2004 awards for a cooperative agreement to support the AIDS Education and Training Centers' (AETCs) National Evaluation Center (NEC). The NEC will provide evaluation services and support to the network of Regional and National AETCs. The purpose of the NEC is to develop, test, and disseminate methods and models for evaluating the impact of clinical education and training on provider behavior and clinical practice, with respect to changes in knowledge and skills, clinical practice behavior, and clinical outcomes.

The purpose of the Regional and National Minority AETCs is to improve the quality of HIV/AIDS clinical care through the training of health care professionals. The Regional and National Minority AETCs enhance the availability of high quality HIV care through training and support of clinical providers, and prioritize the clinical support and training needs of direct medical care providers, including physicians, nurses, physician's assistants, advance practice nurses, pharmacists, and oral health providers. The Regional and National Minority AETCs conduct assessments of regional HIV/AIDS care delivery systems and develop innovative programs to build, through training and support, HIV/AIDS care capacity to fill identified gaps. The Regional and National Minority AETCs target clinical providers caring for communities of color and populations disproportionately affected by the HIV/AIDS virus, particularly providers and those associated with Ryan White Comprehensive AIDS Resources Emergency (CARE) Act supported facilities.

As an active partner in this cooperative agreement, HRSA will have significant involvement with the applicant regarding program plans, policies, and other issues which may have major implications for any activity undertaken by the applicant under the cooperative agreement. HRSA will partner in the development of methods and tools, and selection of pilot sites. HRSA will also review and approve each phase of evaluation studies, and review and process Office of Management and Budget (OMB) Clearance package(s). Additionally, HRSA will assist and guide in program management and evaluation technical assistance. HRSA will participate, as